Dr. John Cush RheumNow
5 years 9 months ago
Amer. College OBGYN practice advisory states women who are Pregnant or lactating should be offered COVID-19 vaccines. These vaccines have not been tested in pregnant women & a pregnancy test is not required to receive the vaccine https://t.co/qdbu8mkKWj
Dr. John Cush RheumNow
5 years 9 months ago
Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f
Dr. John Cush RheumNow
5 years 9 months ago
Global Burden of Disease study published in Arthritis & Rheumatology, shows that in 2017 there were 1.3 billion cases of musculoskeletal disorders worldwide, leading to 121,300 deaths and 138.7 million disability adjusted life years https://t.co/2UDQ0yjTbQ
A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
Dr. John Cush RheumNow
5 years 9 months ago
After meeting with the FDA, Gilead has decided to suspend its application for the use of Filgotinib in RA in the USA. Safety concerns and the 200 mg dose were factors. Gilead believes it needs approval of 100 & 200 mg dose to be competitive in US market https://t.co/aPFN7hH4zH
Dr. John Cush RheumNow
5 years 9 months ago
COVID Risks in Systemic Autoimmune Patients--There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19.
Read more below.
https://t.co/SbMWR3slc3 https://t.co/Tul2W0YtLv
Dr. John Cush RheumNow
5 years 9 months ago
Rheumatologists: Record your question or case for the RheumNow podcast.
https://t.co/wzNmOzH4VE https://t.co/ct3K3KhWmX
Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture.
Dr. John Cush RheumNow
5 years 9 months ago
Lookback at #ACR20. Drs. Cush and Kavanaugh discuss AS/SpA reports from ACR 2020 with Dr. John Reveille and Dr. Olga Petryna.
https://t.co/DWLhD84IrI https://t.co/f8hQXbcvUQ
Dr. John Cush RheumNow
5 years 9 months ago
FDA Updates Session: Dr. Kathryn Dao ( @KDAO2011) reviews the FDA updates session from #ACR20.
https://t.co/ZmHU82AeQu https://t.co/RsCKh88JRq
Dr. John Cush RheumNow
5 years 9 months ago
Tune in to the RheumNow podcast. Find us on Apple or Android devices.
https://t.co/DPZUT2mqdA https://t.co/sHBzIsbRQn
Dr. John Cush RheumNow
5 years 9 months ago
NHANES study shows Peripheral neuropathy (11.6-13.5% population) was common and was independently associated with significant increase in all cause mortality (31-49% increased) in the U.S. population, even in the absence of diabetes. https://t.co/cjreodUIpa
Dr. John Cush RheumNow
5 years 9 months ago
Red Flags and Detours -- New RA Guidelines: Dr. Jack Cush dons his bullet-proof vest before taking aim at the new ACR RA Guidelines at presented at #ACR20.
https://t.co/ZhfCiP59Qu https://t.co/5sui7b6wZ5
Dr. John Cush RheumNow
5 years 9 months ago
Addressing Fatigue in Rheumatoid Arthritis: Dr Eric Dein ( @ejdein1)
#acr20
https://t.co/iKdwJqNlPE https://t.co/2u9pEH0QVq
